ACR 2022 Tweet by Olga Petryna

Tweet
Olga Petryna @DrPetryna Nov 12, 2022
View on
#acrbest #abst0004 #acr22 @rheumnow 🐁 model of excessive mTORC1 activation in JIA confirms unrestricted activation of mTORC1 sufficient to trigger sJIA-like syndrome including MAS w/hemophagocytosis. rapamycin prevents MAS & ⬇️ arthritis severity & bone erosion in Il1rn-/- mice
Image from Olga Petryna’s tweet

Related Content

Article Education/ACR/EULAR

What’s New in Macrophage Activation Syndrome Therapeutics

Bella Mehta, MBBS, MS Jun 9, 2026
MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Topics

×